Blood cancer treatment is entering a new era, bringing powerful breakthroughs that offer renewed hope to people living with leukemia, lymphoma, myeloma, and other blood cancers. Cutting-edge targeted ...

OPTI-AML, a sub-study of Beat AML, compared the standard 28-day venetoclax schedule with a 14-day schedule, both given with ...

Scientists announced two major molecular genetics breakthroughs: a targeted antibody-drug conjugate for acute myeloid leukemia and a CRISPR-based diagnostic that distinguishes multiple viruses by ...

Preclinical study results suggest that targeting Hippo signaling may help address treatment resistance in acute myeloid leukemia.

CPX-351 improved overall survival among older patients with myelodysplastic-related AML who undergo hematopoietic transplantation. CPX-351 treatment resulted in improved overall survival (OS) among ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I think that the last year to two years ...

(RTTNews) - Ipsen (IPSEY, IPN.PA) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for IPN60340 in combination with venetoclax and azacitidine (Ven-Aza ...

As blood cancers are constantly evolving and developing mutations that grow resistance to current treatments, researchers in the University of Cincinnati Cancer Center's Leukemia and Drug Development ...